Industry Briefs: July 2, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: July 2, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Arena Pharmaceuticals and Eisai have received FDA approval for a new molecular entity, Belviq (lorcaserin hydrochloride), for treating chronic weight management. Read More

Astellas Pharma has received approval for a new molecular entity, Myrbetriq (mirabegron) extended-release, for treating adults with overactive bladder. Read More

Biogen Idec and Isis Pharmaceuticals have announced a global collaboration for an antisense program targeting myotonic dystrophy. Read More

Encap Drug Delivery has invested $2 million to expand its facilities, for equipment for product mixing and capsule-filling. Read More

GEA Pharma Systems has agreed to supply a continuous manufacturing line for solid-dose products to an undisclosed pharmaceutical company. Read More

Janssen-Cilag, a Johnson & Johnson subsidiary, has completed the acquisition of Corimmun, a privately held German-based drug-development company. Read More

Takeda Farmacêutica Brasil, a subsidiary of Takeda Pharmaceutical has completed its acquisition of Multilab. Read More

People News

Alnylam Pharmaceuticals has expanded its management team. The company has appointed Oved Amitay as vice-president, head of commercial; Akshay Vaishnaw as executive vice-president and chief medical officer; Jared Gollob as vice-president of clinical research; and Lubomir Nechev as vice-president of process sciences. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here